Monte Rosa Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.33 Intrinsic Value $6.70median of 2 methodsbased on filings through 30 Jun 2026 Market Price $11.26Price as of 1 Oct 2026 OvervaluedIntrinsic value is 41% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $960.6M Enterprise Value $870.5M Shares Outstanding 85.3M diluted Next Earnings Date31 Dec 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Monte Rosa Therapeutics is a leading clinical-stage biotechnology company pioneering molecular glue degraders (MGDs). Backed by a robust proprietary discovery engine (QuEEN™) and a massive $671 million cash reserve that extends its runway into 2029, the company is on the cusp of multiple Phase 2 clinical transitions. Its strategic partnership with Novartis for MRT-6160, valued at up to $2.1 billion in milestones, provides strong external validation and non-dilutive funding. Near-term clinical readouts, particularly the H2 2026 GFORCE-1 data for MRT-8102, serve as major de-risking catalysts. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$25.00 Mean target$28.50 High · most bullish analyst$37.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $25.00 The bear case is driven by potential clinical setbacks, such as safety signals or dose-limiting toxicities in the MRT-8102 or MRT-2359 trials, leading to development delays. Additionally, any strategic deprioritization or delay by Novartis regarding the MRT-6160 program would severely impact investor sentiment and push back anticipated milestone revenues. Base CaseCentral scenario $28.50 Matches the consensus meanThe base case assumes steady pipeline execution with positive, incremental clinical data. MRT-8102 successfully completes its GFORCE-1 trial in H2 2026, confirming its safety profile and profound CRP reduction, leading to the planned Phase 2 initiations. Novartis initiates Phase 2 trials for MRT-6160 in late 2026. MRT-2359 begins its Phase 2 combination study with apalutamide in Q3 2026 as scheduled. Bull CaseUpside scenario $37.00 The bull case assumes rapid clinical validation across all three lead programs. MRT-8102 demonstrates exceptional efficacy in ASCVD and gout, triggering accelerated Phase 2 development. Novartis aggressively advances MRT-6160 in multiple autoimmune indications, unlocking early milestone payments. MRT-2359 shows deep and durable responses in mCRPC patients with AR mutations, positioning it as a best-in-class combination therapy. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |